Literature DB >> 7790701

Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha.

N Hiramatsu1, N Hayashi, A Kasahara, H Hagiwara, T Takehara, Y Haruna, M Naito, H Fusamoto, T Kamada.   

Abstract

To investigate the histological change (change of liver fibrosis) produced by the anti-viral effect of interferon on hepatitis C virus, 40 patients with chronic hepatitis C treated with natural interferon alpha were divided according to the existence of viremia at the end of treatment and 6 months after the end of treatment. The condition of liver fibrosis was scored numerically with a new "hepatic fibrosis score" which is sensitive to more subtle changes than Knodell's fibrosis score. Each portal zone was evaluated separately. End-of-treatment biopsy for the HCV RNA-negative group (negative for HCV RNA at the end of treatment) showed a significant improvement of the "hepatic fibrosis score" as well as the alleviation of necrosis and inflammation. At the end of treatment and 6 months after that, serum procollagen type III peptide levels and serum type IV collagen-7s levels had also decreased significantly in the HCV RNA-negative group. The present study showed that treatment with interferon alpha could alleviate fibrosis in addition to necrosis and inflammation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790701     DOI: 10.1016/0168-8278(95)80420-x

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  16 in total

Review 1.  Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis.

Authors:  Y Inagaki; I Okazaki
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

2.  Cardiac fibroblast transcriptome analyses support a role for interferogenic, profibrotic, and inflammatory genes in anti-SSA/Ro-associated congenital heart block.

Authors:  Robert M Clancy; Androo J Markham; Tanisha Jackson; Sara E Rasmussen; Miroslav Blumenberg; Jill P Buyon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

3.  Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Tsugiko Oze; Naoki Hiramatsu; Nao Kurashige; Natsuko Tsuda; Takayuki Yakushijin; Tatsuya Kanto; Tetsuo Takehara; Akinori Kasahara; Michio Kato; Harumasa Yoshihara; Kazuhiro Katayama; Shinji Kubota; Taizo Hijioka; Kazunobu Ishibashi; Masahide Oshita; Hideki Hagiwara; Yoshimichi Haruna; Eiji Mita; Shinji Tamura; Norio Hayashi
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

4.  The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.

Authors:  Tsugiko Oze; Naoki Hiramatsu; Takayuki Yakushijin; Kiyoshi Mochizuki; Kazuho Imanaka; Akira Yamada; Masahide Oshita; Akira Kaneko; Hideki Hagiwara; Eiji Mita; Toshifumi Ito; Toshihiko Nagase; Yoshiaki Inui; Taizo Hijioka; Shinji Tamura; Harumasa Yoshihara; Eijiro Hayashi; Yasuharu Imai; Michio Kato; Atsushi Hosui; Takuya Miyagi; Yuichi Yoshida; Hisashi Ishida; Tomohide Tatsumi; Shinichi Kiso; Tatsuya Kanto; Akinori Kasahara; Tetsuo Takehara; Norio Hayashi
Journal:  J Gastroenterol       Date:  2011-05-07       Impact factor: 7.527

5.  Improvement of molar ratio of branched-chain amino acids to tyrosine (BTR) associated with liver fibrosis in chronic hepatitis C patients treated with interferon-alpha.

Authors:  T Ninomiya; S Yoon; M Sugano; Y Kumon; Y Seo; K Shimizu; H Nagano; M Kasuga; Y Hayashi
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

6.  Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.

Authors:  H Senturk; O Uzunalimoglu; Y Batur; I Simsek; A Mert; G Ozbay; H Cetinkaya; G Ersoz; F Tabak; H Akbaylar; M Akdogan; A Dokmeci; A Sonsuz; S Ozenirler; E Erden; N Tozum
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

7.  Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment.

Authors:  J F Dufour; R DeLellis; M M Kaplan
Journal:  Dig Dis Sci       Date:  1998-12       Impact factor: 3.199

Review 8.  Innate immunity and alcoholic liver fibrosis.

Authors:  Won-Il Jeong; Bin Gao
Journal:  J Gastroenterol Hepatol       Date:  2008-03       Impact factor: 4.029

9.  Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects.

Authors:  Junichi Tanabe; Akiko Izawa; Natsumi Takemi; Yasushi Miyauchi; Yuichi Torii; Hiromi Tsuchiyama; Tomohiko Suzuki; Saburo Sone; Kazuki Ando
Journal:  Immunology       Date:  2007-07-20       Impact factor: 7.397

10.  Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis.

Authors:  Ilker Tasci; Mehmet Refik Mas; Sevil Atalay Vural; Salih Deveci; Bilgin Comert; Gunay Alcigir; Nuket Mas; Cemal Akay; Mithat Bozdayi; Cihan Yurdaydin; Hakan Bozkaya; Ozden Uzunalimoglu; Ahmet Turan Isik; Harun M Said
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.